HOME >> MEDICINE >> NEWS
Melanoma vaccine developed at the University of Virginia shows promise in clinical trial

CHARLOTTESVILLE, Va., Oct. 30 A multi-peptide vaccine to treat melanoma resulted in an immune response from 75 percent of the patients and is associated with tumor regression, according to a randomized, phase II clinical trial involving more than two dozen patients with advanced melanoma at the University of Virginia Health System. The trial also reveals what may be the most effective treatment regimen to activate an immune response from the body against melanoma. The results are published in the Nov. 1 edition of the Journal of Clinical Oncology found online at www.jco.org.

Melanoma is the most serious form of skin cancer. According to the American Cancer Society, more than 53,000 new cases of the disease are expected this year, and about 7,400 people will die of melanoma. Peptides are molecules consisting of two or more amino acids linked by a peptide bond.

"There have been significant tumor regressions on this protocol of peptide vaccines against melanoma," said Dr. Craig L. Slingluff, Jr., professor of surgery and director of the Human Immune Therapy Center at U.Va. "This gives us hope that this approach may be useful for patients with advanced disease."

In the trial, 26 patients with stage III or IV melanoma received six vaccinations of a mixture of four melanoma peptides developed at U.Va., followed by a tetanus helper peptide and low-dose interleukin-2. In one-half of the patients, the peptides were injected in an emulsion including a cytokine called granulocyte macrophage-colony stimulating factor (GMCSF.) In the other half, the peptides were injected after being pulsed on dendritic cells.

The results showed that the immune response against melanoma was greater in patients vaccinated with the GMCSF emulsion. Responses by the immune system's killer or cytotoxic t-cells were observed in the lymph nodes draining the vaccine site in 80 percent of patients on the GMCSF arm, and in the
'"/>

Contact: Bob Beard
reb8e@virginia.edu
434-982-4490
University of Virginia Health System
30-Oct-2003


Page: 1 2

Related medicine news :

1. University Of Pittsburgh Cancer Institute Defines First Immunologic Markers Of Interferon Effectiveness Against Melanoma
2. Melanoma Patients Sentinel Lymph Nodes (SLNS) Play A Strong Role In Disease Prognosis, UCSF Study Reports
3. Jefferson Researchers Report Progress In Using Vaccinia-Based Vaccine For Melanoma
4. Vaccine Against Melanoma Proves Successful For Patients With Disease Spread To Two Lymph Node Areas
5. DNA-Based Cancer Vaccine Shows Promise To Successfully Treat Melanoma In Mice
6. Pitt marks 50th anniversary of its Salk polio vaccine with reunion, scientific symposium
7. NIAID initiates trial of experimental avian flu vaccine
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Invasive pneumonia and antibiotic resistance decreased after childhood vaccine introduced
10. Earlier use of prostate cancer vaccines urged by Hopkins scientists
11. Researchers close in on breast cancer vaccine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/1/2020)... ... September 01, 2020 , ... Feeding Matters , the first organization in ... Disorder (PFD), is pleased to announce that the U.S. Centers for Disease Control and ... in the next edition of the U.S. International Classification of Diseases (ICD ) ...
(Date:8/31/2020)... ... ... found out your dear friend has cancer? , It’s hard to hear your doctor say ... diagnosis. Once the shock wears off, the questions and fears can be overwhelming. , How ... to help? Words are failing me. I’m scared. I want to DO something. , We’ve ...
(Date:8/31/2020)... ... August 31, 2020 , ... ... services to dental groups in the United States, today announced the grand opening ... Beaumont, CA. , Patients will enjoy convenient hours, a comfortable office, and ...
(Date:8/31/2020)... ... 31, 2020 , ... Bonde Innovations, LLC, a venture-backed developer ... failure, today announced that the company has been awarded a Phase 1 Small ... Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). The ...
(Date:8/28/2020)... ... August 28, 2020 , ... With in-person ... out to continue helping the specialty-diet community connect with great, gluten-free brands. At ... coupons, enter giveaways, chat with brands & watch over 50 educational classes... all ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... (PRWEB) , ... September 01, 2020 , ... September is ... women, accounting for more deaths than any other cancer of the female reproductive system. ... diagnosed with ovarian cancer and about 14,000 women will die from this disease. ...
(Date:8/31/2020)... (PRWEB) , ... August 31, 2020 , ... ... research and advisory guide, has named Cloudticity a Gold winner in the 15th ... industry and peer recogniti o ns from Network Products Guide honoring ...
(Date:8/27/2020)... ... August 27, 2020 , ... ... today announced the successful completion of their 2020 System and Organizational Controls (SOC) ... HITRUST® interim assessment and MARS-E compliance assessment. These achievements reflect their long-standing commitment ...
Breaking Medicine Technology:
Cached News: